245 related articles for article (PubMed ID: 24272998)
1. Palmitic acid and DGAT1 deficiency enhance osteoclastogenesis, while oleic acid-induced triglyceride formation prevents it.
Drosatos-Tampakaki Z; Drosatos K; Siegelin Y; Gong S; Khan S; Van Dyke T; Goldberg IJ; Schulze PC; Schulze-Späte U
J Bone Miner Res; 2014; 29(5):1183-95. PubMed ID: 24272998
[TBL] [Abstract][Full Text] [Related]
2. Palmitic Acid Reduces Circulating Bone Formation Markers in Obese Animals and Impairs Osteoblast Activity via C16-Ceramide Accumulation.
Alsahli A; Kiefhaber K; Gold T; Muluke M; Jiang H; Cremers S; Schulze-Späte U
Calcif Tissue Int; 2016 May; 98(5):511-9. PubMed ID: 26758875
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of triglyceride synthesis does not enhance palmitate lipotoxicity or prevent oleate-mediated rescue in rat hepatocytes.
Leamy AK; Hasenour CM; Egnatchik RA; Trenary IA; Yao CH; Patti GJ; Shiota M; Young JD
Biochim Biophys Acta; 2016 Sep; 1861(9 Pt A):1005-1014. PubMed ID: 27249207
[TBL] [Abstract][Full Text] [Related]
4. DGAT1 deficiency decreases PPAR expression and does not lead to lipotoxicity in cardiac and skeletal muscle.
Liu L; Yu S; Khan RS; Ables GP; Bharadwaj KG; Hu Y; Huggins LA; Eriksson JW; Buckett LK; Turnbull AV; Ginsberg HN; Blaner WS; Huang LS; Goldberg IJ
J Lipid Res; 2011 Apr; 52(4):732-44. PubMed ID: 21205704
[TBL] [Abstract][Full Text] [Related]
5. Diet-Induced Obesity and Its Differential Impact on Periodontal Bone Loss.
Muluke M; Gold T; Kiefhaber K; Al-Sahli A; Celenti R; Jiang H; Cremers S; Van Dyke T; Schulze-Späte U
J Dent Res; 2016 Feb; 95(2):223-9. PubMed ID: 26450512
[TBL] [Abstract][Full Text] [Related]
6. Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis.
Bharti AC; Takada Y; Aggarwal BB
J Immunol; 2004 May; 172(10):5940-7. PubMed ID: 15128775
[TBL] [Abstract][Full Text] [Related]
7. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
8. α-Linolenic Acid Inhibits Receptor Activator of NF-κB Ligand Induced (RANKL-Induced) Osteoclastogenesis and Prevents Inflammatory Bone Loss via Downregulation of Nuclear Factor-KappaB-Inducible Nitric Oxide Synthases (NF-κB-iNOS) Signaling Pathways.
Song J; Jing Z; Hu W; Yu J; Cui X
Med Sci Monit; 2017 Oct; 23():5056-5069. PubMed ID: 29061958
[TBL] [Abstract][Full Text] [Related]
9. RANKL stimulates inducible nitric-oxide synthase expression and nitric oxide production in developing osteoclasts. An autocrine negative feedback mechanism triggered by RANKL-induced interferon-beta via NF-kappaB that restrains osteoclastogenesis and bone resorption.
Zheng H; Yu X; Collin-Osdoby P; Osdoby P
J Biol Chem; 2006 Jun; 281(23):15809-20. PubMed ID: 16613848
[TBL] [Abstract][Full Text] [Related]
10. Ca(2+)-dependent permeabilization of mitochondria and liposomes by palmitic and oleic acids: a comparative study.
Belosludtsev KN; Belosludtseva NV; Agafonov AV; Astashev ME; Kazakov AS; Saris NE; Mironova GD
Biochim Biophys Acta; 2014 Oct; 1838(10):2600-6. PubMed ID: 24997274
[TBL] [Abstract][Full Text] [Related]
11. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
12. Short-term effects of dietary fatty acids on muscle lipid composition and serum acylcarnitine profile in human subjects.
Kien CL; Everingham KI; D Stevens R; Fukagawa NK; Muoio DM
Obesity (Silver Spring); 2011 Feb; 19(2):305-11. PubMed ID: 20559306
[TBL] [Abstract][Full Text] [Related]
13. TNF‑α and RANKL promote osteoclastogenesis by upregulating RANK via the NF‑κB pathway.
Luo G; Li F; Li X; Wang ZG; Zhang B
Mol Med Rep; 2018 May; 17(5):6605-6611. PubMed ID: 29512766
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
[TBL] [Abstract][Full Text] [Related]
15. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
16. Iguratimod inhibits osteoclastogenesis by modulating the RANKL and TNF-α signaling pathways.
Li CH; Ma ZZ; Jian LL; Wang XY; Sun L; Liu XY; Yao ZQ; Zhao JX
Int Immunopharmacol; 2021 Jan; 90():107219. PubMed ID: 33307512
[TBL] [Abstract][Full Text] [Related]
17. DGAT1 inhibitors protect pancreatic β-cells from palmitic acid-induced apoptosis.
Huang JS; Guo BB; Wang GH; Zeng LM; Hu YH; Wang T; Wang HY
Acta Pharmacol Sin; 2021 Feb; 42(2):264-271. PubMed ID: 32737468
[TBL] [Abstract][Full Text] [Related]
18. Specific RANK Cytoplasmic Motifs Drive Osteoclastogenesis.
Li Y; Shi Z; Jules J; Chen S; Kesterson RA; Zhao D; Zhang P; Feng X
J Bone Miner Res; 2019 Oct; 34(10):1938-1951. PubMed ID: 31173390
[TBL] [Abstract][Full Text] [Related]
19. Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-κB and PI3K/Akt signaling pathways.
Yuan FL; Xu RS; Jiang DL; He XL; Su Q; Jin C; Li X
Bone; 2015 Jun; 75():128-37. PubMed ID: 25708053
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological characterization of [trans-5'-(4-amino-7,7-dimethyl-2-trifluoromethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)-2',3'-dihydrospiro(cyclohexane-1,1'-inden)-4-yl]acetic acid monobenzenesulfonate (JTT-553), a novel acyl CoA:diacylglycerol transferase (DGAT) 1 inhibitor.
Tomimoto D; Okuma C; Ishii Y; Akiyama Y; Ohta T; Kakutani M; Ohkuma Y; Ogawa N
Biol Pharm Bull; 2015; 38(2):263-9. PubMed ID: 25747985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
